10-Q: Alphatec Holdings Reports 22% Revenue Increase in Q1 2025, Completes Convertible Notes Offering and Debt Repurchase

Alphatec Holdings announces a 22% increase in revenue for Q1 2025, driven by product volume growth and strategic financial maneuvers including a convertible notes offering and debt repurchase.

Summary

• Alphatec Holdings, Inc. reported a 22% increase in revenue for the three months ended March 31, 2025, reaching $169.18 million compared to $138.48 million in the same period of 2024.
• The increase in revenue was primarily due to higher product volume, an expanded product portfolio, and increased adoption of the company's technology.
• Cost of sales increased by 29% to $53.18 million, driven by higher product volume and increased stock-based compensation.
• Research and development expenses decreased by 8% to $16.58 million, mainly due to lower stock-based compensation and personnel costs.
• Sales, general, and administrative expenses increased by 12% to $127.02 million, driven by higher compensation-related costs and variable selling expenses.
• Litigation-related expenses increased significantly by 176% to $12.21 million due to a litigation settlement.
• The company issued $405.0 million in 0.75% Senior Convertible Notes due 2030 and used a portion of the proceeds to repurchase 80% of its 2026 convertible notes for $268.4 million.
• The net loss for the quarter was $51.91 million, or $0.35 per share, compared to a net loss of $48.50 million, or $0.34 per share, for the same period in 2024.
• Cash and cash equivalents increased to $153.24 million at March 31, 2025, from $138.84 million at December 31, 2024.
• The company believes its existing funds, cash from operations, and access to financing are adequate to meet its working capital, capital expenditure, and debt service requirements.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. Revenue growth is strong, and the company is actively managing its debt. However, the net loss remains significant, and litigation expenses are high. Overall, the sentiment is cautiously optimistic.

Positives

• Revenue increased by 22% year-over-year, indicating strong growth in the company's core business.
• The issuance of new convertible notes and repurchase of existing debt demonstrates proactive financial management.
• Cash and cash equivalents increased, providing financial flexibility.
• The company's strategic distribution channel continues to be built out.

Negatives

• Net loss remained significant at $51.91 million.
• Litigation-related expenses increased substantially due to a settlement.
• Cost of sales increased at a higher rate (29%) than revenue growth (22%).

Risks

• The company's future performance is subject to various risks and uncertainties, including those related to market conditions, regulatory requirements, and competition.
• Litigation is inherently unpredictable, and unfavorable resolutions could materially affect the company's financial results.
• The company is obligated to meet certain minimum purchase commitment requirements with a third-party supplier through December 2026, which could impact financial flexibility.

Future Outlook

The company anticipates that its existing funds, cash generated from operations, and existing sources of financing will be adequate to satisfy its needs for working capital, capital expenditure, debt service requirements, and other business initiatives.

Management Comments

• The application of our teams deep spine know-how, coupled with a willingness to invest holistically in the technologies integrated into our procedural approaches continues to increasingly compel surgeons and sales talent to partner with us.
• That adoption-driven validation has been the source of industry-leading market share expansion, which has delivered an approximately 40% revenue compound annual growth rate since our transformation commenced in 2018.

Industry Context

Alphatec's focus on spine disorders and its integrated technology platform positions it to capitalize on the growing demand for advanced spinal surgery solutions. The company's growth rate suggests it is gaining market share in a competitive industry.

Comparison to Industry Standards

• While a direct comparison to industry standards requires a deeper dive into competitors' results, the 22% revenue growth suggests Alphatec is performing competitively.
• Companies like Medtronic, Johnson & Johnson (DePuy Synthes), and Stryker are major players in the broader medical device market, including spine, and their growth rates can serve as benchmarks.
• However, Alphatec's smaller size allows for potentially higher growth rates compared to these larger, more established companies.
• The 40% revenue compound annual growth rate since 2018 is a strong indicator of successful transformation and market share expansion.

Legal Proceedings

• In April 2025, the Company entered into a settlement in principle with a shareholder to resolve a legal dispute.
• The Company recorded the amount of the settlement, which is included in litigation-related expenses in the condensed consolidated statements of operations and accrued expenses and other current liabilities on the condensed consolidated balance sheets for the period ended March 31, 2025.

Related Party Transactions

• The Company purchases inventory from an affiliate of Squadron Capital, LLC (the Squadron Supplier Affiliate).
• David Pelizzon, President and Director of Squadron Capital, LLC, currently serves on the Company's Board of Directors.
• For the three months ended March 31, 2025 and 2024, the Company purchased inventory in the amounts of $2.8 million and $4.7 million, respectively, from the Squadron Supplier Affiliate.
• As of March 31, 2025, and December 31, 2024, the Company had $2.7 million and $1.8 million, respectively, due to the Squadron Supplier Affiliate, for inventory purchases.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses, but encouraged by the revenue growth and strategic debt management.
• Employees may benefit from the company's growth and expansion, but also face potential uncertainty due to restructuring and cost management efforts.
• Customers (hospitals and surgeons) should benefit from the company's continued innovation and product development.

Next Steps

• The company intends to use the remainder of the net proceeds from the 2030 Notes for general corporate purposes.
• The company will continue to add clinically astute and exclusive sales team members to reach untapped surgeons, hospitals, and national accounts and better penetrate existing accounts and territories.

Key Dates

Keywords

Alphatec, convertible notes, spine, revenue, medical technology, financial results